Integrated metabolomics and ligand fishing approaches to screen the hypoglycemic ingredients from four Coptis medicines
Integrated metabolomics and ligand fishing approaches to screen the hypoglycemic ingredients from four Coptis medicines
复制标题
DOI:
10.1016/j.jpba.2020.113655
复制
发表时间:
2021-01-05
影响因子:
3.4
通讯作者:
Ma, Yuntong
中科院分区:
文献类型:
--
作者:
Chen, Yang;Qi, Luming;Ma, Yuntong
Rhizoma Coptidis, which is mainly originated from the rhizomes of Coptis chinensis, C. deltoidea, C. omeiensis and C. teeta, has been proved to possess a superior anti-diabetic effect in clinic. However, the metabolic characterization and the hypoglycemic ingredients among these Coptis species remain unclear. In this study, we employed an integrated strategy to screen the bioactive ingredients based on metabolomics and ligand fishing approaches. First, the ultra high-performance liquid chromatography coupled to quadruple time-of-flight tandem mass spectrometry (UHPLC-Q-TOF-MSIMS) was used for qualitative identification of four Coptis rhizomes. After prescreening by alpha-glucosidase inhibition assay, an affinity ultrafiltration system was constructed to fish out hypoglycemic ingredients from the fractions with superior activity, and verified by molecular docking on a virtual platform. The distribution of major compounds suggested the four Coptis rhizomes possess similar metabolic profiles, mainly including alkaloids and phenylpropanoids. Besides, eight compounds (magnoflorine, groenlandicine, jatrorrhizine, epiberberine, columbamine, coptisine, palmatine and berberine) from the n-butanol fraction were specifically bound to alpha-glucosidase, and considered as hypoglycemic ingredients of Rhizoma Coptidis. Molecular docking revealed that the inhibitors bound to alpha-glucosidase mainly by hydrophobic interaction, hydrogen bond interaction and pi-pi interaction. Summary, this research leads a more systematic and comprehensive study on metabolic characterization and hypoglycemic ingredients of Rhizoma Coptidis, which can provide a theoretical basis for the further clinical application. (C) 2020 Elsevier B.V. All rights reserved.